Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
William L. Conte, Lilian Golzarri‐Arroyo
Multiple Sclerosis and Related Disorders (2022) Vol. 63, pp. 103905-103905
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
Myron J. Levin, Andrew Ustianowski, S. Thomas, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 7, pp. 1247-1256
Open Access | Times Cited: 27
Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis
Saad Alhumaid, Abbas Al Mutair, Jalal Alali, et al.
Diseases (2022) Vol. 10, Iss. 4, pp. 118-118
Open Access | Times Cited: 24
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?
Thomas Müller, Peter Riederer, W. Kuhn
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 2, pp. 101-107
Closed Access | Times Cited: 14
Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
Juthaporn Cowan, Ashley Amson, Anna Christofides, et al.
International Journal of Infectious Diseases (2023) Vol. 134, pp. 228-238
Open Access | Times Cited: 14
Serum neutralization of SARS‐CoV‐2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld
Qianqian Zhao, Xin Wang, Ze Zhang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 7
Open Access | Times Cited: 13
Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
Dejan Jakimovski, Svetlana Eckert, Omid Mirmosayyeb, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 350-350
Open Access | Times Cited: 12
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
Joseph J. Sabatino, Kristen Mittl, William Rowles, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 70, pp. 104484-104484
Open Access | Times Cited: 14
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products
Rosaria Talarico, Giuseppe A. Ramirez, Sofia Barreira, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 5
Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
Federica Dominelli, Maria Antonella Zingaropoli, Matteo Tartaglia, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy
Yoo Jin Lee, Hyun‐Ki Kim, You Jin Kim, et al.
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2533-2539
Closed Access | Times Cited: 1
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
Andrew Ustianowski
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 12, pp. 1517-1527
Closed Access | Times Cited: 6
Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience
Stefano Gelibter, Fiammetta Pirro, Lorenzo Saraceno, et al.
Journal of Neuroimmunology (2023) Vol. 383, pp. 578199-578199
Closed Access | Times Cited: 3
Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
María Fernández-Prada, Jaime Jesús Pérez‐Martín, P. Cienfuegos-González
Medicina Clínica (English Edition) (2023) Vol. 160, Iss. 10, pp. 458-459
Open Access | Times Cited: 2
Seguridad e inmunogenicidad de cilgavimab-tixagevimab para la profilaxis preexposición frente a la COVID-19 en pacientes inmunodeprimidos
María Fernández-Prada, Jaime Jesús Pérez‐Martín, P. Cienfuegos-González
Medicina Clínica (2023) Vol. 160, Iss. 10, pp. 458-459
Open Access | Times Cited: 2
Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder
Dominika Šťastná, Marta Vachová, Pavel Dušek, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 85, pp. 105523-105523
Closed Access
Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies
Sarah Conway, Saumya Gupta, Brian C. Healy, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 87, pp. 105680-105680
Closed Access
Analysis of Evusheld safety and efficacy in multiple sclerosis patients
Emilie N. Liu, M. Vila Real, Jennifer H. Yang, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 88, pp. 105733-105733
Closed Access
Multiple Sclerosis and COVID-19: An Overview on Risk, Severity, and Association With Disease Modifying Therapies
Mary Hollist, Abraham Hollist, Katherine Au, et al.
Neuroscience Insights (2024) Vol. 19
Open Access
Central Nervous System Neuroimmunologic Complications of COVID-19
Kathryn B. Holroyd, Sarah Conway
Seminars in Neurology (2023) Vol. 43, Iss. 02, pp. 229-250
Closed Access | Times Cited: 1
Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence
Manuela Altieri, Rosario Domenico Melisi, Miriana Conte, et al.
Neurological Sciences (2023) Vol. 44, Iss. 11, pp. 4107-4110
Closed Access | Times Cited: 1
Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab Plus COVID19 Antivirals for the Treatment of Early COVID-19
Nicolina Capoluongo, Annamaria Mascolo, Francesca Futura Bernardi, et al.
(2023)
Open Access | Times Cited: 1
Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak
Jianhua You, Jiaxin Tian, Haidi Wu, et al.
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 12, pp. 1365-1371
Closed Access | Times Cited: 1
Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
Nicolina Capoluongo, Annamaria Mascolo, Francesca Futura Bernardi, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1493-1493
Open Access | Times Cited: 1
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables
Stefania Barone, Camillo Palmieri, Luca Gallelli, et al.
Neurotherapeutics (2023) Vol. 21, Iss. 2, pp. e00307-e00307
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top